Gotta say it - although it's not 'new' news, the 19.6 month median survival rate for castrate-resistant prostate cancer is an outstanding result. Let's not lose sight of that, and the fact this was achieved despite some of the patients being on sub-optimal doses. The final two hurdles as I see it are to demonstrate unequivocally the added value Idroxonil provides to LU-PSMA, and to secure IP (I take comfort in the recent change of stance from the US Patent Office, resulting in a reset of the claim process).
All in all, happy to be invested in this, and well done Dr Kelly for creating multiple opportunities to demonstrate the drug's worth. What a shame he wasn't given the chance to do the same with Cantrixil, the next-generation drug to Idronoxil - a completely squandered opportunity by those who forced Dr Kelly out of his own company, and then slumbered like dogs in a manger, showing no initiative whatsoever to promote the drug, and finally selling it for a song.
- Forums
- ASX - By Stock
- Ann: Noxopharm Presents to H.C. Wainwright Global Conference
Gotta say it - although it's not 'new' news, the 19.6 month...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M |
Open | High | Low | Value | Volume |
12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6612 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 99714 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6612 | 0.115 |
6 | 681590 | 0.110 |
5 | 132523 | 0.105 |
5 | 532405 | 0.100 |
1 | 25357 | 0.098 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 99714 | 1 |
0.125 | 261572 | 5 |
0.130 | 134000 | 3 |
0.135 | 361881 | 5 |
0.140 | 241192 | 9 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |